Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is expected to continue its growth trajectory with its continuous glucose monitoring systems, both in the traditional diabetic patient market and in the expanding consumer biosensor market. With its focus on software and engagement, an impressive product pipeline, and a strong management team, DexCom is poised for continued success in the industry. However, potential risks include increased competition, delays in product releases, and potential pricing pressures.

Bears say

DexCom is facing regulatory risks with potential delays in launching new products and potential pricing pressures from payors. They also face high levels of investment and competition in the diabetes device sector, making profitability challenging. Despite positive data on the benefits of their CGM technology, there may be concerns about sustainability and adoption on a larger scale, indicating a potential risk to their long-term growth and financial success.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.